Inhibrx Biosciences, Inc. INBX Business Segments — Nonoperating Income (Expense)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s business segments — nonoperating income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s business segments — nonoperating income (expense)?
- Inhibrx Biosciences, Inc. (INBX) reported business segments — nonoperating income (expense) of -$2.51M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s business segments — nonoperating income (expense) changed year-over-year?
- Inhibrx Biosciences, Inc.'s business segments — nonoperating income (expense) decreased by 513.2% year-over-year, from -$410K to -$2.51M.
- What does business segments — nonoperating income (expense) mean?
- This metric includes financial results from activities outside the company's core business operations, such as interest income, interest expense, and foreign exchange gains or losses. It reflects the impact of capital structure and treasury management on the company's bottom line. Investors use this to isolate the performance of the core business from financial market fluctuations.